Oral probiotics,
does it really help with Treatment of symptoms in established atopic dermatitis or eczema?
research showsOral probiotics are rated F for treating established eczema. Gore 2012 randomized 137 infants, and the primary 12-week analysis of about 133 failed on the between-group SCORAD endpoint (P=0.7). The Cochrane review concerned treatment of established eczema, not prevention. Across 39 randomized trials and 2,599 participants, patient-rated symptoms were -0.44 on a 20-point scale (-1.22 to 0.33; 13 trials, 754 participants), and total SCORAD was -3.91 (-5.86 to -1.96; 24 trials, 1,596 participants). Even the confidence-limit maximum falls below the 8.7-point minimal clinically important difference from Schram et al., Allergy 2012;67:99-106.
ads claimMicrobiome changes or immune-marker signals must not be converted into confirmed relief of itch, sleep loss, or skin lesions, and prevention evidence must not be presented as treatment of established disease.
Useful facts when choosing a product
- Probiotic effects are strain-, dose-, and viability-specific and cannot automatically transfer across products.
- Prevention of eczema and treatment after eczema has developed are distinct claims.
- Core care includes emollients, trigger management, and appropriate topical anti-inflammatory treatment when needed; probiotics should not replace them.
What the research actually shows
Gore 2012 randomized 137 infants with eczema, and the primary 12-week analysis of about 133 failed on between-group SCORAD at P=0.7. Makrgeorgou 2018 reviewed treatment of established eczema rather than prevention. Across 39 trials and 2,599 participants, patient-rated symptoms were -0.44 on a 20-point scale (-1.22 to 0.33; 13 trials, 754 participants), and total SCORAD was -3.91 (-5.86 to -1.96; 24 trials, 1,596 participants). The confidence interval excluded the 8.7-point threshold from Schram 2012.
Why this is classified as F (18)
The pivotal trial failed on its primary endpoint, and 39 randomized trials found patient symptoms null and total SCORAD far below the clinically important threshold in the same established-eczema treatment indication. Repeated failure supports F with 18 points.
Counterpoint. Future efficacy from a new specific strain remains possible, but available retail probiotics as a class are not established eczema treatments.
Rejudgment record. Cross-check applied — This evidence concerns treatment of established eczema, not prevention. The pivotal primary 12-week analysis of about 133 failed on between-group SCORAD at P=0.7. Across 39 randomized trials and 2,599 participants, patient-rated symptoms were -0.44 on a 20-point scale (-1.22 to 0.33; 13 trials, 754 participants), and total SCORAD was -3.91 (-5.86 to -1.96; 24 trials, 1,596 participants). Even the confidence-limit maximum was below the 8.7-point minimal clinically important difference from Schram et al., Allergy 2012;67:99-106, excluding clinical benefit and supporting F
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement of infant eczema SCORAD over 12 weeks | F | The primary endpoint failed at P=0.70 among 133 actually analyzed participants. |
| Improvement of patient- or parent-rated itch and sleep symptoms | F | The pooled result from 13 trials and 754 participants was null at -0.44 on a 20-point scale. |
| Clinically meaningful reduction in eczema severity | F | The total SCORAD difference of -3.91 points was far below the 8.7-point minimal clinically important difference. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Gore C et al. 2012 | Single-center randomized double-blind three-arm placebo-controlled 12-week trial | 133 | Nestec Ltd and the North West Lung Research Centre Endowment Fund; included manufacturer funding | Primary change in SCORAD at 12 weeks | Primary endpoint failed: B. lactis 12.8, L. paracasei 12.5, placebo 11.8 points, P=0.70; secondary outcomes also showed no differences. | Pivotal direct null trial |
| Makrgeorgou A et al. 2018 | Cochrane systematic review and meta-analysis of randomized trials treating established eczema, not prevention | 1,596 | Public NIHR Cochrane Skin infrastructure funding; 10 included trials were funded by probiotic suppliers and four did not report funding | Patient-rated symptoms, quality of life, and total SCORAD | Symptoms -0.44 on a 20-point scale (-1.22 to 0.33); total SCORAD -3.91 (-5.86 to -1.96). Even the confidence-limit maximum was below the 8.7-point Schram 2012 threshold. | Cumulative repeated counterevidence in the same indication |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Oral probiotics x treatment of established atopic dermatitis and eczema — Evidence Grade F·18. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/oral-probiotics-treatment-established-eczema/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.